| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 952 | 778 | 800 | 811 | 1,223 | 1,029 | 989 | 1,086 | 974 | 986 | 1,025 | 1,098 | 1,242 | 1,193 | 1,564 | 1,585 | 1,557 | 1,483 | 1,673 | 1,784 | 1,621 | 1,712 | 1,765 | 1,885 | 2,060 | 1,808 | 1,945 | 2,223 | 2,476 | 2,217 | 2,384 | 3,020 | 3,929 | 3,516 | 3,551 | 4,135 | 3,912 | 4,543 | 3,604 | 3,826 | 4,415 | 3,990 |
| Expenses | 653 | 606 | 727 | 615 | 740 | 719 | 706 | 762 | 738 | 735 | 786 | 836 | 937 | 886 | 982 | 1,160 | 1,137 | 1,029 | 1,174 | 1,307 | 1,247 | 1,284 | 1,363 | 1,459 | 1,476 | 1,427 | 1,515 | 1,733 | 1,911 | 1,783 | 1,894 | 2,624 | 2,820 | 2,741 | 2,769 | 3,051 | 3,013 | 2,813 | 2,905 | 3,070 | 3,339 | 3,193 |
| EBITDA | 300 | 172 | 73 | 196 | 483 | 309 | 283 | 324 | 236 | 250 | 239 | 262 | 306 | 307 | 582 | 425 | 420 | 454 | 499 | 477 | 373 | 428 | 402 | 427 | 584 | 380 | 430 | 489 | 565 | 434 | 490 | 396 | 1,109 | 775 | 782 | 1,084 | 900 | 1,730 | 699 | 756 | 1,077 | 797 |
| Operating Profit % | 21 % | 20 % | 6 % | 22 % | 21 % | 27 % | 25 % | 27 % | 20 % | 21 % | 19 % | 21 % | 20 % | 21 % | 26 % | 25 % | 26 % | 29 % | 25 % | 25 % | 20 % | 24 % | 22 % | 21 % | 20 % | 19 % | 18 % | 20 % | 21 % | 17 % | 18 % | 11 % | 25 % | 20 % | 18 % | 14 % | 22 % | 17 % | 18 % | 19 % | 23 % | 18 % |
| Depreciation | 59 | 59 | 61 | 64 | 65 | 66 | 68 | 70 | 73 | 99 | 94 | 97 | 95 | 99 | 112 | 117 | 120 | 124 | 132 | 144 | 152 | 167 | 178 | 186 | 184 | 195 | 202 | 206 | 212 | 218 | 231 | 301 | 364 | 358 | 389 | 415 | 407 | 405 | 420 | 425 | 436 | 455 |
| Interest | 0 | 4 | 3 | 2 | 21 | 6 | 7 | 9 | 5 | 16 | 14 | 15 | 17 | 18 | 19 | 19 | 16 | 17 | 14 | 18 | 17 | 13 | 7 | 5 | 34 | 20 | 23 | 15 | 11 | 20 | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 |
| Profit Before Tax | 249 | 165 | 20 | 141 | 409 | 238 | 208 | 245 | 159 | 135 | 132 | 150 | 193 | 190 | 451 | 289 | 284 | 313 | 354 | 315 | 204 | 249 | 218 | 236 | 366 | 166 | 206 | 269 | 343 | 197 | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 |
| Tax | 32 | 34 | 18 | 19 | 55 | 55 | 42 | 54 | 10 | 38 | 43 | 36 | 41 | 52 | 73 | 46 | 41 | 85 | 100 | 85 | 45 | 81 | 22 | 49 | 69 | 57 | 46 | 49 | 59 | 30 | 147 | -5 | 82 | 35 | 42 | 55 | 96 | 284 | 71 | 75 | 27 | 8 |
| Net Profit | 217 | 131 | 2 | 122 | 354 | 182 | 167 | 191 | 148 | 98 | 89 | 114 | 153 | 138 | 378 | 243 | 243 | 228 | 254 | 230 | 159 | 168 | 195 | 187 | 296 | 108 | 160 | 220 | 284 | 167 | 82 | -21 | 415 | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 |
| EPS in ₹ | 10.08 | 6.31 | -0.54 | 5.30 | 16.97 | 8.49 | 7.48 | 8.72 | 6.49 | 1.38 | 1.17 | 1.56 | 2.21 | 1.02 | 3.00 | 3.67 | 3.61 | 1.74 | 1.82 | 1.71 | 1.04 | 1.26 | 1.39 | 1.42 | 2.13 | 0.71 | 1.16 | 1.57 | 2.00 | 1.21 | 0.39 | -0.35 | 2.62 | 0.85 | 1.05 | 5.52 | 1.13 | 5.51 | -0.13 | 0.21 | 2.88 | 0.26 |
Biocon
Biocon
365.75
+5.30
(1.47%)
Key Fundamentals
Market Cap
48,190.90 Cr
EPS
8.46
PE Ratio
74.52
Dividend Yield
0.12 %
Industry
Healthcare 52 Week High
406.00
52 Week Low
291.00
PB Ratio
1.87
Debt to Equity
0.84
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from16 analysts
Actual
Company News
View All News
Biocon Biologics received Health Canada approval for Yesintek and Yesintek I.V., biosimilars to Stelara (ustekinumab). The approval was granted on October 17, enabling Canadian commercial availability in mid-October. The biosimilars are indicated for treating moderate to severe plaque psoriasis in adults and pediatric patients, active psoriatic arthritis in adults, and moderately to severely active Crohn's disease and ulcerative colitis in adults. Health Canada's approval was based on comprehensive data confirming Yesintek is highly similar to Stelara with no clinically meaningful differences in efficacy, safety and immunogenicity. This marks Biocon Biologics' expansion into the Canadian market following their U.S. launch, strengthening their North American presence and immunology portfolio. The company has commercialized 10 biosimilars serving over 6 million patients across 120+ countries.
Biocon chief Kiran Mazumdar-Shaw met with Karnataka Chief Minister Siddaramaiah and Deputy Chief Minister D K Shivakumar during Deepavali greetings, assuring cooperation for Bengaluru's development. Shaw has been vocal about the city's infrastructure problems through social media posts. Deputy CM Shivakumar confirmed that industry leaders have agreed to cooperate with Bengaluru's development and will not hurt the city. He announced plans to call meetings with IT/BT industry leaders and visit local bodies adjacent to the Greater Bengaluru Authority area. The state government has faced criticism over poor road conditions and traffic issues from industry veterans including Shaw and former Infosys CFO Mohandas Pai. Shivakumar had previously alleged that Shaw and Pai had personal agendas, which Shaw rejected, stating both had criticized infrastructure deterioration under previous governments. Shaw also met veteran BJP leader B S Yediyurappa and BJP MLA C N Ashwath Narayan, who congratulated her on being ranked the 3rd richest woman in the world.
Biocon Biologics Expands Civica Partnership to Launch Private-Label Insulin Glargine in U.S.
Oct 16, 2025
Oct 16, 2025Biocon Biologics has expanded its strategic collaboration with Civica to include a new Insulin Glargine medicine for the U.S. market. Under the multi-year agreement, Biocon Biologics will manufacture and supply Insulin Glargine to Civica, while Civica will commercialize the product under its own label and trade dress, with CalRx branding in California. Biocon Biologics retains ownership of intellectual property and marketing authorization, and will continue direct commercialization of its own Insulin Glargine-yfgn medicine. The partnership aims to increase supply of affordable insulin for 38.4 million U.S. diabetes patients. This builds on their existing relationship where Biocon Biologics provides Civica with Insulin Aspart drug substance. Biocon Biologics is the fourth largest insulin company globally, providing over 9.2 billion doses of insulin worldwide.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,687.00 | #1 4,06,351.40 | 38.94 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 60.73 | |
6,438.50 | 1,72,289.10 | 74.05 | 9,712.00 | 18.67 | 2,191 | 26.74 | 57.08 | |
1,568.10 | 1,27,948.20 | 23.55 | 28,409.50 | 7.12 | 5,291 | 9.88 | 50.34 | |
3,576.50 | 1,21,718.50 | 60.48 | 11,539.40 | 6.99 | 1,911 | 19.91 | 50.97 | |
1,289.40 | 1,07,189.40 | #1 18.77 | 33,741.20 | 16.73 | 5,725 | -0.38 | 57.78 | |
1,001.25 | 1,02,017.00 | 21.39 | 23,511.00 | 18.55 | 4,615 | 2.60 | 50.49 | |
2,406.50 | 99,751.30 | 51.89 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 35.88 | |
1,918.70 | 87,829.30 | 23.57 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 42.45 | |
5,432.00 | 65,467.80 | 27.84 | 13,458.30 | 3.70 | 2,216 | 21.39 | 44.72 | |
1,099.40 | 63,580.40 | 19.01 | 32,345.60 | 9.43 | 3,484 | -10.24 | 50.73 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
5.43 %
Net Income Growth
10.14 %
Cash Flow Change
37.49 %
ROE
0.58 %
ROCE
1.95 %
EBITDA Margin (Avg.)
-0.38 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Fixed Assets | 1,630 | 1,749 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 | 31,963 |
| Current Assets | 2,563 | 3,971 | 4,048 | 4,149 | 4,823 | 5,325 | 7,600 | 8,382 | 12,334 | 15,179 | 16,286 |
| Capital Work in Progress | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 | 8,508 |
| Investments | 230 | 901 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 | 1,127 |
| Other Assets | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,311 | 7,406 | 8,127 | 13,189 | 16,434 | 17,199 |
| Total Liabilities | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Current Liabilities | 1,555 | 1,666 | 1,678 | 2,141 | 3,038 | 4,008 | 4,210 | 3,828 | 8,511 | 15,359 | 14,334 |
| Non Current Liabilities | 1,378 | 2,493 | 2,502 | 2,200 | 2,448 | 3,053 | 5,805 | 7,096 | 21,043 | 15,437 | 16,751 |
| Total Equity | 3,443 | 4,300 | 5,214 | 5,649 | 6,707 | 7,383 | 8,508 | 9,470 | 22,489 | 25,275 | 27,713 |
| Reserve & Surplus | 3,171 | 3,992 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 | 21,044 |
| Share Capital | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -94 | 300 | -47 | -261 | 210 | 165 | 72 | -243 | 641 | -380 | 2,004 |
| Investing Activities | -491 | -1,138 | -510 | -684 | -703 | -1,505 | -3,651 | -1,662 | -14,260 | -1,002 | -203 |
| Operating Activities | 211 | 371 | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | 1,853 | 2,954 | 4,061 |
| Financing Activities | 186 | 1,068 | -178 | -240 | -242 | 388 | 2,564 | 242 | 13,049 | -2,333 | -1,854 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 60.67 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 54.45 % | 54.45 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 7.96 % | 6.55 % | 5.63 % | 5.90 % | 5.93 % | 5.66 % | 5.66 % | 6.04 % | 6.61 % |
| DIIs | 6.65 % | 6.89 % | 6.87 % | 6.83 % | 7.79 % | 7.30 % | 7.76 % | 8.63 % | 11.90 % | 12.56 % | 14.08 % | 14.51 % | 13.68 % | 14.30 % | 14.44 % | 15.37 % | 15.72 % | 22.82 % | 22.10 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 10.89 % | 11.03 % | 11.49 % | 11.37 % | 10.87 % | 10.72 % | 12.07 % | 12.46 % | 13.21 % | 13.34 % | 13.61 % | 14.47 % | 15.53 % | 14.63 % | 14.57 % | 14.07 % | 13.63 % | 12.58 % | 12.71 % |
| Others | 21.79 % | 21.44 % | 21.00 % | 21.16 % | 20.70 % | 21.35 % | 19.54 % | 18.27 % | 14.26 % | 13.46 % | 3.70 % | 3.83 % | 4.52 % | 4.53 % | 4.42 % | 4.27 % | 4.34 % | 4.10 % | 4.12 % |
| No of Share Holders | 0 | 3,11,349 | 3,38,815 | 3,63,447 | 3,64,502 | 3,47,911 | 3,41,016 | 3,69,816 | 4,11,086 | 4,12,441 | 4,15,046 | 4,34,339 | 4,70,261 | 4,43,513 | 4,39,503 | 4,27,705 | 4,24,297 | 4,30,217 | 4,13,191 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3 | 1 | 1 | 0.00 | 0.00 | 0.5 | 1.5 | 0.5 | 0.5 |
| Dividend Yield (%) | 0.00 | 1.01 | 0.33 | 0.37 | 0.00 | 0.00 | 0.25 | 0.57 | 0.15 | 0.14 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 11 Nov 2025 |  Quarterly Result Announcement | NA | 11 Nov 2025 | 352.25 | 359.80 |
| 13 Jun 2019 |  Bonus | 1:1 | 12 Jun 2019 | 271.45 | 257.90 |
| 01 Jul 2022 |  Dividend | ₹ 0.50 /share | 30 Jun 2022 | 382.30 | 308.40 |
| 07 Jul 2023 | Dividend | ₹ 1.50 /share | 07 Jul 2023 | 240.45 | 259.50 |
| 05 Jul 2024 | Dividend | ₹ 0.50 /share | 05 Jul 2024 | 311.90 | 361.10 |
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 311.90 | 339.20 |
| 30 Oct 2024 | Quarterly Result Announcement | NA | 30 Oct 2024 | 370.65 | 326.85 |
| 30 Jan 2025 | Quarterly Result Announcement | NA | 30 Jan 2025 | 372.95 | 355.70 |
| 08 May 2025 | Quarterly Result Announcement | NA | 08 May 2025 | 339.10 | 346.50 |
| 04 Jul 2025 | Dividend | ₹ 0.50 /share | 04 Jul 2025 | 346.50 | 374.40 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 372.05 | 360.60 |
| 08 Aug 2025 | Annual General Meeting | NA | 08 Aug 2025 | 346.50 | 364.20 |
Announcements
Intimation Of Change In Name Of Step-Down Subsidiaries Of The Company5 days ago
5 days agoPress Release5 days ago
5 days agoPress ReleaseOct 16, 2025
Oct 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Oct 13, 2025Company StatementOct 11, 2025
Oct 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 09, 2025
Oct 09, 2025Submission Of Copy Of Biocon India Limited Employees Welfare Trust Amendment DeedOct 09, 2025
Oct 09, 2025Notification To Stock ExchangesOct 07, 2025
Oct 07, 2025Board Meeting Intimation for Intimation Of The Date Of Board MeetingOct 06, 2025
Oct 06, 2025Board Meeting Outcome for Early Redemption Of NcdsOct 01, 2025
Oct 01, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 01, 2025
Oct 01, 2025Board Meeting Intimation for Proposed Early Redemption Of Unlisted Secured Rated Redeemable Non-Convertible Debentures (Ncds).Sep 28, 2025
Sep 28, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Announcement Under Regulation 30 - Receipt Of Show Cause NoticeSep 25, 2025
Sep 25, 2025Buyback Of Commercial PaperSep 19, 2025
Sep 19, 2025Intimation Of Record Date For Buy Back Of Listed Commercial Paper Issued By The CompanySep 17, 2025
Sep 17, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 17, 2025
Sep 17, 2025Letters To Shareholders Under 100 Days Campaign - Saksham NiveshakSep 13, 2025
Sep 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 12, 2025
Sep 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 11, 2025
Sep 11, 2025Email Communication To Shareholders Under 100 Days Campaign - Saksham NiveshakSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 09, 2025
Sep 09, 2025Board Meeting Outcome for Outcome Of Board MeetingSep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 05, 2025
Sep 05, 2025Company StatementSep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 02, 2025
Sep 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 29, 2025
Aug 29, 2025Notification To Stock ExchangesAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Aug 20, 2025Transcript Of Earnings Call Q1 FY26Aug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 14, 2025
Aug 14, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Aug 09, 2025ChairpersonS Speech At The 47Th Annual General Meeting Of The CompanyAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 08, 2025
Aug 08, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-AcquisitionAug 07, 2025
Aug 07, 2025Outcome Of Board Meeting - AcquisitionAug 07, 2025
Aug 07, 2025Board Meeting Outcome for Financial Results For June 30 2025Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 07, 2025
Aug 07, 2025Financial Results For The Quarter Ended June 30 2025Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 23, 2025
Jul 23, 2025Company StatementJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 18, 2025
Jul 18, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 17, 2025
Jul 17, 2025Mutual Fund Holdings
Quant ELSS Tax Saver Fund Direct-Growth 
HSBC Midcap Fund Direct-Growth 
Kotak Arbitrage Fund Direct-Growth 
Invesco India Arbitrage Fund Direct-Growth 
Tata Arbitrage Fund Direct - Growth 
Axis India Manufacturing Fund Direct-Growth 
Bajaj Finserv Large and Mid Cap Fund Direct-Growth 
Aditya Birla Sun Life Multi-Cap Fund Direct-Growth 
HDFC Arbitrage Fund Wholesale Direct-Growth 
Edelweiss Arbitrage Fund Direct-Growth 
Nippon India Multi Cap Fund Direct-Growth 
SBI Arbitrage Opportunities Fund Direct-Growth 
ICICI Prudential Equity Arbitrage Direct-Growth 
Mirae Asset Multicap Fund Direct - Growth 
UTI Arbitrage Fund Direct-Growth 
Baroda BNP Paribas Arbitrage Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 53.92
ATR(14)
Less Volatile 7.59
STOCH(9,6)
Neutral 77.24
STOCH RSI(14)
Neutral 64.11
MACD(12,26)
Bullish 1.45
ADX(14)
Weak Trend 12.98
UO(9)
Bearish 45.84
ROC(12)
Uptrend And Accelerating 3.28
WillR(14)
Neutral -34.21
About Biocon
Biocon Limited is India's largest fully-integrated biopharmaceutical company, focusing on biotechnology products and research services. Founded in 1978, Biocon specializes in treating diabetes, cancer, and autoimmune diseases. The company develops and commercializes novel biologics, biosimilars, complex small molecule APIs, and generic formulations for global markets. Biocon's product portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, and oncology treatments. The company operates manufacturing facilities in Bangalore, Hyderabad, and Visakhapatnam, utilizing various technology platforms such as microbial fermentation, chromatographic purification, chemical synthesis, and peptide synthesis. Biocon has expanded its global presence through strategic partnerships and has launched several biosimilar and generic products in international markets, including the United States, Europe, and emerging economies.
Listing Date
07 Apr, 2004(21 Years,
22 days)
Website
Chairperson NameKiran Mazumdar Shaw
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
